Last reviewed · How we verify

Mylotarg — Competitive Intelligence Brief

Mylotarg (gemtuzumab-ozogamicin) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CD33-directed Immunoconjugate [EPC]. Area: Oncology.

marketed CD33-directed Immunoconjugate [EPC] Myeloid cell surface antigen CD33 Oncology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Mylotarg (gemtuzumab-ozogamicin) — Pfizer. Mylotarg works by binding to CD33 on cancer cells and releasing a toxic compound that kills the cells.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Mylotarg TARGET gemtuzumab-ozogamicin Pfizer marketed CD33-directed Immunoconjugate [EPC] Myeloid cell surface antigen CD33 2000-01-01
Mylotarg GEMTUZUMAB Wyeth Pharms Inc marketed CD33-directed Immunoconjugate [EPC] Myeloid cell surface antigen CD33 2020-01-01
GEMTUZUMAB OZOGAMICIN GEMTUZUMAB OZOGAMICIN marketed CD33-directed Immunoconjugate [EPC] 2000-01-01
OZOGAMICIN OZOGAMICIN marketed CD33-directed Immunoconjugate [EPC]

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CD33-directed Immunoconjugate [EPC] class)

  1. · 2 drugs in this class
  2. Pfizer · 1 drug in this class
  3. Wyeth Pharms Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Mylotarg — Competitive Intelligence Brief. https://druglandscape.com/ci/gemtuzumab-ozogamicin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: